All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
27 results for "Cancer" and "Gynecologic Cancers" and "Lymphoma"
Composite Health Assessment Risk Model for Older Adults: Applying Pre-transplant Comorbidity, Geriatric Assessment and Biomarkers to Predict Non-Relapse Mortality after Allogeneic Transplantation in Older Adults
Composite Health Assessment Risk Model (CHARM) for Older Adults
Protocol No
CTN-1704
Sub Category
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1- Antitrypsin (AAT) Combined with Corticosteroids vs. Corticosteroids Alone for the Treatment of High-Risk Acute Graft-versus-Host-Disease (GVHD) Following Hematopoietic Stem Cell Transplant
Alpha 1- Antitrypsin Combined with Corticosteroids vs. Corticosteroids Alone for Tx of aGVHD
Protocol No
CTN-1705
Sub Category
A Phase 1, Multicenter, Open-label, Multiple-ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of KPG-818 in Subjects with Hematological Malignancies
Open-label, multiple-ascending dose study to evaluate the safety, PK, and preliminary clinical activity of KPG-818 as a single agent in adult subjects with selected hematological malignancies, except for multiple myeloma indication. KPG-818 will be used in combination with dexamethasone for dose escalation and dose expansion. The study will consist of 2 parts: Part 1 dose escalation and Part 2 dose expansion.
Protocol No
KANGPU-KPG-818-HEM-101
A multi-center single arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Dual CD20 and CD19 Specific Chimeric Antigen Receptor in Subjects with Relapsed and/or Refractory Diffuse Large B Cell Lymphoma
Phase II MB-CART2019.1 for R/R DLBCL
Protocol No
MILTENYI-MB-CART2019-1-DLBCL
Sub Category
A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma-Delta T Cells in Adults with Refractory B-Cell Malignancies, in Monotherapy and Combination with IL-2.
A Phase 1 Study of ADI-001 in B Cell Malignancies
Protocol No
ADICET-ADI-001-BCELL
Sub Category
A Phase III, Randomized Study Of Nivolumab (OPDIVO) Plus AVD Or Brentuximab Vedotin (ADCETRIS) Plus AVD In Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Nivo plus AVD or BV plus AVD in newly diagnosed advanced HL
Protocol No
SWOG-S1826-HL
Sub Category
A Multicenter, Phase 1, Open-Label, Dose-Escalation and Expansion Study Of TNB-486, A Bispecific Antibody, In Subjects With Relapsed Or Refractory B-Cell Non-Hodgkin Lymphoma
A Study of TNB-486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Protocol No
TENEOBIO-TENEOTWO-TNB486-001
An Open-Label, Phase 1/2 Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)
Study Evaluating Safety and Efficacy of JCAR017 in Subject with rrCLL or SLL
Protocol No
JUNO-017004-TRANSCEND-CLL
Sub Category
A Phase II Study of Split-Dose R-CHOP in Older Adults with Diffuse Large B-cell Lymphoma
Split-Dose R-CHOP for Older Adults with DLBCL
Protocol No
WON-SHAH-UW18131-SPLIT-RCHOP
Sub Category
A Phase I Trial of Neihulizumab Monotherapy for Standard-Risk Acute GVHD
A Phase I Trial of Neihulizumab Monotherapy for Standard-Risk Acute GVHD
Protocol No
IIT-ABEDIN-NEIHULIZUMAB
Sub Category
A Phase I Study of Neihulizumab (AbGn-168H) in Patients with Steroid-refractory Acute Graft-Versus-Host Disease (sr-aGvHD)
Neihulizumab (AbGn-168H) in patients with steroid-refractory acute graft-versus-host disease
Protocol No
ABGENOMICS-2017-002-01
Sub Category
A randomized 3-arm Phase II study comparing 1) Bendamustine, Rituximab and high dose Cytarabine (BR/CR), 2) Bendamustine, Rituximab, high dose Cytarabine and Acalabrutinib (BR/CR-A), and 3) Bendamustine, Rituximab and Acalabrutinib (BR-A) in patients </= 70 years old with untreated Mantle Cell Lymphoma
Comparison of BR/CR, BR/CR-A, and BR-A in patients under 70 with untreated MCL.
Protocol No
ECOG-EA4181-MCL
Sub Category
A Phase II, Open-Label, Study of Propylene Glycol-Free Melphalan HCL (EVOMELA®) in Combination with Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation
EVOMELA In Combination With Fludarabine and TBI based reduced intensity conditioning for Haplo BMT
Protocol No
IIT-HAMADANI-FLU-MEL-TBI
Sub Category
A Phase II Study of Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) after Allogeneic Hematopoietic Cell Transplantation (HCT)
A Phase II Study of Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) after AlloHCT
Protocol No
DF-HCC-18-265-BOS
Sub Category
Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic BMT
Protocol No
CTN-1702
Sub Category
A Phase II, Single-Arm, Open-label Study of Itacitinib, for the prevention of cytokine Release Syndrome (CRS) induced by Immune Effector Cell Therapy
A study of Itacitinib for the Prevention of CRS induced by Immune Effector Cell Therapy
Protocol No
INCYTE-INCB-39110-211-CRS
Sub Category
Phase 1, Open Label, Multicenter, Dose Escalation Study of YTB323 in Adult Patients with CLL/SLL and DLBCL
YTB323 (CD19-specific CAR-T Cells) in patients with CLL/SLL and DLBCL
Protocol No
NOVARTIS-YTB323A12101
Sub Category
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Ibrutinib Before and After Stem Cell Transplant in Treating Patients With R/R DLBCL
Protocol No
ALLIANCE-A051301-CTN1201
Sub Category
MolecularTemplates-MT-3724: Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients with Relapsed or Refractory DLBCL (MT-3724-NHL-001)
Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL (MT-3724NHL001)
Protocol No
MOLECULARTEMPLATES-MT-3724-NHL
Sub Category
A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission
Rituximab with or without SCT in Treating Pt with MRD-Neg MCL in First Complete Remission
Protocol No
ECOG-EA4151
Sub Category
A Phase II Trial of Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease
Tidrakizumab for Prevention of Acute Graft-Versus-Host Disease
Protocol No
IIT-RUNAAS-TILDRAKIZUMAB-AGVHD
Sub Category